Literature DB >> 182716

Plaque reduction neutralization test for human cytomegalovirus based upon enhanced uptake of neutral red by virus-infected cells.

N J Schmidt, J Dennis, E H Lennette.   

Abstract

Foci of cells infected with human cytomegalovirus were noted to stain more intensely than uninfected cells with neutral red, and this provided the basis for development of a plaque assay and plaque reduction neutralization test for cytomegalovirus. Plaques demonstrable by neutral red staining could be counted at 8 days after infection; thus, results could be obtained earlier than for plaque assay systems based upon the viral cytopathic effect, a fewer manipulations were required for staining cell monolayers to demonstrate plaques. Certain variables affecting plaque size and numbers and antibody titers were defined. Addition of fresh guinea pig complement to the reaction mixtures markedly enhanced cytomegalovirus-neutralizing antibody titers of hyperimmune animal sera, but titers of human sera were enhanced only two-or fourfold.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 182716      PMCID: PMC274391          DOI: 10.1128/jcm.4.1.61-66.1976

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  11 in total

1.  A PLAQUE REDUCTION NEUTRALIZATION TEST FOR HUMAN CYTOMEGALOVIRUS.

Authors:  G PLUMMER; M BENYESH-MELNICK
Journal:  Proc Soc Exp Biol Med       Date:  1964-10

2.  Neutralizing antibodies to cytomegaloviruses in normal simian and human sera.

Authors:  Y Minamishima; B J Graham; M Benyesh-Melnick
Journal:  Infect Immun       Date:  1971-10       Impact factor: 3.441

3.  Cytomegalovirus neutralization by plaque reduction.

Authors:  H K Andersen
Journal:  Arch Gesamte Virusforsch       Date:  1971

4.  Complement-requiring neutralizing antibodies in hyperimmune sera to human cytomegaloviruses.

Authors:  B J Graham; Y Minamishima; G R Dresman; H G Haines; M Benyesh-Melnick
Journal:  J Immunol       Date:  1971-12       Impact factor: 5.422

5.  The influence of complement on cytomegalovirus neutralization by antibodies.

Authors:  H K Andersen
Journal:  Arch Gesamte Virusforsch       Date:  1972

6.  Plaque assay of cytomegalovirus strains of human origin.

Authors:  B B Wentworth; L French
Journal:  Proc Soc Exp Biol Med       Date:  1970-11

7.  Human cytomegalovirus. I. Purification and characterization of viral DNA.

Authors:  E S Huang; S T Chen; J S Pagano
Journal:  J Virol       Date:  1973-12       Impact factor: 5.103

8.  Thermoinactivation of human cytomegalovirus.

Authors:  V Vonka; M Benyeshmelnick
Journal:  J Bacteriol       Date:  1966-01       Impact factor: 3.490

9.  Three-day assay for human cytomegalovirus applicable to serum neutralization tests.

Authors:  J L Waner; J E Budnick
Journal:  Appl Microbiol       Date:  1973-01

10.  Propagation and purification of high-titer human cytomegalovirus.

Authors:  R W Chambers; J A Rose; A S Rabson; H E Bond; W T Hall
Journal:  Appl Microbiol       Date:  1971-11
View more
  14 in total

1.  Protective MCMV immunity by vaccination of the salivary gland via Wharton's duct: replication-deficient recombinant adenovirus expressing individual MCMV genes elicits protection similar to that of MCMV.

Authors:  Guangliang Liu; Fangfang Zhang; Ruixue Wang; Lucille London; Steven D London
Journal:  FASEB J       Date:  2014-01-03       Impact factor: 5.191

2.  Antisera to human cytomegalovirus produced in hamsters: reactivity in radioimmunoassay and other antibody assay systems.

Authors:  B Forghani; N J Schmidt; E H Lennette
Journal:  Infect Immun       Date:  1976-11       Impact factor: 3.441

3.  Improved glycine-extracted complement-fixing antigen for human cytomegalovirus.

Authors:  J D Kettering; N J Schmidt; E H Lennette
Journal:  J Clin Microbiol       Date:  1977-12       Impact factor: 5.948

4.  Anti-complement immunofluorescence test for antibodies to human cytomegalovirus.

Authors:  J D Kettering; N J Schmidt; D Gallo; E H Lennette
Journal:  J Clin Microbiol       Date:  1977-12       Impact factor: 5.948

5.  Host cellular annexin II is associated with cytomegalovirus particles isolated from cultured human fibroblasts.

Authors:  J F Wright; A Kurosky; E L Pryzdial; S Wasi
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

6.  A new method for the determination of virus specific IgG and IgM antibodies. Brief report.

Authors:  W A Schmidt; M Klein
Journal:  Arch Virol       Date:  1980       Impact factor: 2.574

7.  Rapid neutralization assay for human cytomegalovirus antibody.

Authors:  M Zerbini; M Plazzi; M Musiani
Journal:  J Clin Microbiol       Date:  1985-06       Impact factor: 5.948

8.  Differentiation of cytomegalovirus antigens by their reactivity with various classes of human antibodies in the indirect fluorescent antibody test.

Authors:  J L Riggs; N E Cremer
Journal:  J Clin Microbiol       Date:  1980-01       Impact factor: 5.948

9.  Engineered Mesenchymal Cells Improve Passive Immune Protection Against Lethal Venezuelan Equine Encephalitis Virus Exposure.

Authors:  Lorena R Braid; Wei-Gang Hu; John E Davies; Les P Nagata
Journal:  Stem Cells Transl Med       Date:  2016-06-22       Impact factor: 6.940

10.  Novel microneutralization assay for HCMV using automated data collection and analysis.

Authors:  Anna Maria Abai; Larry R Smith; Mary K Wloch
Journal:  J Immunol Methods       Date:  2007-02-23       Impact factor: 2.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.